Morgan Stanley on Pfizer (PFE): 'we believe generic versions of Vyndaqel could still represent a potential headwind to the franchise'

April 28, 2026 10:53 AM

Morgan Stanley analyst Terence Flynn reiterated an Equalweight rating and $28.00 price target on Pfizer (NYSE: PFE).The analyst comments "PFE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Morgan Stanley on Pfizer (PFE): 'we believe generic versions of Vyndaqel could still represent a potential headwind to the franchise'

Categories